What is NSCLC Phase I MEDI4736 Tremelimumab Study?
CATEGORY:
MEDI4736 Tremelimumab is a phase 1 trial assessing the safety and tolerability of MEDI4736 with tremelimumab in patients with non-small cell lung cancer (NSCLC).
Save up to 80% off your prescriptions!
How do members experience NSCLC Phase I MEDI4736 Tremelimumab Study?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Adenocarcinoma (non-small cell lung cancer) | 1 | 0 | |
| Lung carcinoid tumor | 1 | 1 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Ulcerative colitis | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 1 | |
| Moderate | 0 | |
| Mild | 0 | |
| None | 0 |
Learn more about our community’s experience with NSCLC Phase I MEDI4736 Tremelimumab Study
What are people saying about NSCLC Phase I MEDI4736 Tremelimumab Study?
2
2
members have reported taking NSCLC Phase I MEDI4736 Tremelimumab Study
Join the conversation and connect with people who have taken NSCLC Phase I MEDI4736 Tremelimumab Study
Last updated: